Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT06807593
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ustekinumab — DRUGGiven by infusion
Study Details
The goal of this clinical research study is to learn if ustekinumab can help to control immune-related diarrhea and/or colitis in cancer patients.
Key Dates
- Start date
- Feb 24, 2026
- Status verified
- Mar 2026
- Primary completion
- Mar 31, 2027
- Completion
- Mar 31, 2027
Study Design
- Enrollment
- 10 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Single ArmParticipants will be identified per the evaluation of primary oncology and/or gastroenterology consult services.
Primary Outcome Measure
Safety and Adverse Events [ Time Frame: Through study completion; an average of 1 year ]
Central Contacts
- Yinghong Wang, MD,PHD(281) 221-9138
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The University of Texas M. D. Anderson Cancer Center | Houston | Texas | 77030 | Yinghong Wang, MD,PHD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
Related Studies
- Childhood Cancer Survivor StudyRecruiting · St. Jude Children's Research Hospital · Birmingham, Alabama
- Long-Term Follow-Up of Recipient of Gene Transfer ResearchRecruiting · M.D. Anderson Cancer Center · Houston, Texas
- Caris Biorepository Research ProtocolRecruiting · Caris Science, Inc. · Mobile, Alabama
- Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-upRecruiting · Center for Biomedical Research, LLC · Jacksonville, Florida